Latest News on Our Investigational COVID-19 Antiviral
October 1, 2021
Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study
This website is designed to provide members of the media with quick and easy access to recent information about Merck. For additional information, please visit 'About Merck'.
For journalists with a media inquiry, please contact us: 1-833-90MERCK (1-833-906-3725).